The use of novel agents in multiple myeloma patients with hepatic impairment

Lindsay C. Stansfield, Wilson I. Gonsalves, Francis K. Buadi

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Novel drugs such as immunomodulators and proteasome inhibitors have improved the survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing based on metabolism and clearance is important to maintain efficacy while avoiding toxicity. Hepatic impairment (HI) in multiple myeloma patients is rare but well described either due to disease or therapy-related factors. However, limited data are available on the appropriate use and dosing of the novel agent therapeutics in myeloma patients with HI. Furthermore, data on HI secondary to the novel agent toxicity are also sparse. This systematic review highlights the evidence on the use of novel agents like thalidomide, lenalidomide, pomalidomide, bortezomib and carfilzomib in patients with HI as well as their associated hepatic toxicities.

Original languageEnglish (US)
Pages (from-to)501-510
Number of pages10
JournalFuture Oncology
Issue number3
StatePublished - Feb 1 2015


  • hepatic impairment
  • myeloma
  • novel agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The use of novel agents in multiple myeloma patients with hepatic impairment'. Together they form a unique fingerprint.

Cite this